ArticleBMC neurology2026
Transcriptomic signatures of gray matter volume loss in cerebral small vessel disease.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundWhite matter hyperintensities (WMHs) are a hallmark imaging sign of cerebral small vessel disease (CSVD) and are closely linked to motor and cognitive deficits. Using voxel‑based morphometry (VBM) together with spatial transcriptomics, this study explored the altered molecular pathways underlying the reduction in gray matter volume (GMV) associated with WMHs.
methodsWe included 25 patients with WMHs and 26 healthy controls. The VBM analysis was used to identify brain regions with reduced GMV. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were then performed using spatial transcriptomic data from the Allen Human Brain Atlas (AHBA) to explore the underlying molecular pathways.
resultsCompared to healthy controls, patients with WMHs exhibited significantly reduced GMV in several key brain regions (p < 0.01, cluster-level corrected). These GMV reductions were widely distributed across the frontal, parietal, temporal, and occipital lobes, as well as the cingulate cortex and cerebellum. A total of 597 genes significantly associated with GMV loss were enriched in core neurobiological pathways, including protein synthesis, RNA metabolism, intracellular protein transport, and protein homeostasis. GO analysis revealed ribosome- and translation-related terms as the most significantly enriched across all three domains—biological process (BP), molecular function (MF), and cellular component (CC)—with structural constituent of ribosome and cytosolic ribosome being the most prominent in the MF and CC categories, respectively. Consistently, KEGG pathway analysis highlighted significant enrichment of both the ribosome and spliceosome pathways, further supporting the central role of cellular stress responses, DNA repair, and lysosomal function in the observed GMV-associated genes.
conclusionsWMHs-related gray matter atrophy may be spatially associated with coordinated perturbations in RNA metabolism and ribosome-mediated translation, together with dysregulated DNA metabolic processes and altered cellular stress responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.